TY - JOUR
T1 - Launching the Quality Outcomes Database Tumor Registry
T2 - rationale, development, and pilot data
AU - Asher, Anthony L.
AU - Khalafallah, Adham M.
AU - Mukherjee, Debraj
AU - Alvi, Mohammed Ali
AU - Yolcu, Yagiz U.
AU - Khan, Inamullah
AU - Pennings, Jacquelyn S.
AU - Davidson, Claudia A.
AU - Archer, Kristin R.
AU - Moshel, Yaron A.
AU - Knightly, John
AU - Roguski, Marie
AU - Zacharia, Brad E.
AU - Harbaugh, Robert E.
AU - Kalkanis, Steven N.
AU - Bydon, Mohamad
N1 - Publisher Copyright:
© AANS 2022.
PY - 2022/2
Y1 - 2022/2
N2 - OBJECTIVE Neurosurgeons generate an enormous amount of data daily. Within these data lie rigorous, valid, and reproducible evidence. Such evidence can facilitate healthcare reform and improve quality of care. To measure the quality of care provided objectively, evaluating the safety and efficacy of clinical activities should occur in real time. Registries must be constructed and collected data analyzed with the precision akin to that of randomized clinical trials to accomplish this goal. METHODS The Quality Outcomes Database (QOD) Tumor Registry was launched in February 2019 with 8 sites in its initial 1-year pilot phase. The Tumor Registry was proposed by the AANS/CNS Tumor Section and approved by the QOD Scientific Committee in the fall of 2018. The initial pilot phase aimed to assess the feasibility of collecting outcomes data from 8 academic practices across the United States; these outcomes included length of stay, discharge disposition, and inpatient complications. RESULTS As of November 2019, 923 eligible patients have been entered, with the following subsets: intracranial metastasis (17.3%, n = 160), high-grade glioma (18.5%, n = 171), low-grade glioma (6%, n = 55), meningioma (20%, n = 184), pituitary tumor (14.3%, n = 132), and other intracranial tumor (24%, n = 221). CONCLUSIONS The authors have demonstrated here, as a pilot study, the feasibility of documenting demographic, clinical, operative, and patient-reported outcome characteristics longitudinally for 6 common intracranial tumor types.
AB - OBJECTIVE Neurosurgeons generate an enormous amount of data daily. Within these data lie rigorous, valid, and reproducible evidence. Such evidence can facilitate healthcare reform and improve quality of care. To measure the quality of care provided objectively, evaluating the safety and efficacy of clinical activities should occur in real time. Registries must be constructed and collected data analyzed with the precision akin to that of randomized clinical trials to accomplish this goal. METHODS The Quality Outcomes Database (QOD) Tumor Registry was launched in February 2019 with 8 sites in its initial 1-year pilot phase. The Tumor Registry was proposed by the AANS/CNS Tumor Section and approved by the QOD Scientific Committee in the fall of 2018. The initial pilot phase aimed to assess the feasibility of collecting outcomes data from 8 academic practices across the United States; these outcomes included length of stay, discharge disposition, and inpatient complications. RESULTS As of November 2019, 923 eligible patients have been entered, with the following subsets: intracranial metastasis (17.3%, n = 160), high-grade glioma (18.5%, n = 171), low-grade glioma (6%, n = 55), meningioma (20%, n = 184), pituitary tumor (14.3%, n = 132), and other intracranial tumor (24%, n = 221). CONCLUSIONS The authors have demonstrated here, as a pilot study, the feasibility of documenting demographic, clinical, operative, and patient-reported outcome characteristics longitudinally for 6 common intracranial tumor types.
KW - Quality Outcomes Database
KW - oncology
KW - registry
KW - tumor
UR - http://www.scopus.com/inward/record.url?scp=85122810122&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85122810122&partnerID=8YFLogxK
U2 - 10.3171/2021.1.JNS201115
DO - 10.3171/2021.1.JNS201115
M3 - Article
C2 - 34359037
AN - SCOPUS:85122810122
SN - 0022-3085
VL - 136
SP - 369
EP - 378
JO - Journal of neurosurgery
JF - Journal of neurosurgery
IS - 2
ER -